TeamBest™, through Best Cyclotron Systems, Inc. (BCSI), offers radioisotopes and production capabilities for nuclear medicine and radiotherapy with its range of cyclotron systems. BCSI’s mission is to create technology to provide healthcare options for various needs around the world. Our staff assists from the planning stage, detailed design, facility construction, daily production, maintenance and emergency repair through the TeamBest™ network. We provide solutions for PET-CT and molecular imaging radiopharmaceuticals with the same excellent customized care as demonstrated in our 34-year history of radiotherapy support.
BCSI Cyclotron Systems
BCSI staff works with the end user to configure the system for the needs of the user. There are five general energy domains for BCSI cyclotron systems: 14, 25, 28, 35 and 70 MeV. The applications for these accelerator systems are different, and the configurations will reflect that difference.
The BCSI 14p is a 14 MeV proton cyclotron. 14 MeV has been selected to offer a significant 18Fluorine production yield with the investment efficiency of small power costs and low initial cost. As the user moves to other PET radioisotopes, the energy offers adequate production yields of radioisotopes such as 124I and 64Cu with the added benefit of optimized specific activity of the product. The cyclotron system has a small footprint and can be either shielded with integrated (self) shielding or installed in its own shielded room. Production targets for 18F, 11C, 13N, 15O, 64Cu and 124I are available. These systems are designed for individual hospital or small regional pharmacy use.
The BCSI 25p is a 25 MeV proton cyclotron. It is designed to provide additional proton energy to make some specific single photon (SPECT) radioisotopes available for users. Most notable is I123, where the majority of production yield is covered by the 25 MeV energy beam. A group producing a specific radiopharmaceutical can, with the Best 25p, produce their own input material to maintain independence and cost-effective manufacturing. The key feature is a unique design for each application that streamlines cost and production efficiency.
The BCSI 28p is a 28 MeV proton cyclotron, the Cyclotron of choice for research institutions requiring a broad range of radioisotopes and a regional radiopharmacy that supports PET imaging centres as well as providing SPECT molecules. Since the B28 can be upgraded to 35 MeV (see below) and up to 1000 microamperes current, the higher energy and higher current allows even more radioisotope production. In addition, these upgrades can be implemented in the field.
The BCSI 35p is a 35 MeV proton cyclotron. It is designed to produce radioisotopes using the (p,2n) or the (p,3n) reaction. There is a broad range of single photon emitters that are used in nuclear diagnostic imaging and therapy that are accessible in this energy range. TeamBest™ will partner with the end user to create a facility that will satisfy the end user's requirements and provide some of TeamBest's radioisotope supply requirements. Both solid and gas target systems can be added to the BCSI 35p system.
The BCSI 70p is a 70 MeV proton cyclotron. The energy provides access to radionuclides produced by (p,xn) reactions and is a research accelerator as well as a radioisotope production cyclotron. TeamBest™ will partner with the end user to create a facility that will satisfy the end user's requirements and provide some of TeamBest's radioisotope supply requirements, together with the opportunity for joint research projects. Both solid and gas target systems can be added to the BCSI 70p system.
TeamBest™ provides a system that fits the needs of every customer. We offer a turnkey solution — not only the cyclotron, but also targets, automated radiochemistry, infrastructure, operations and maintenance support. As consistent supplies of radioisotopes become more uncertain, particularly for reactor-supplied isotopes, the Best family of cyclotrons provides a Total Solution™ for the medical community with less dependence on unreliable sources.